Trial Profile
Integrating intravenous oxaliplatin plus oral capecitabine with pelvic radiation for rectal cancer.
Status:
Completed
Phase of Trial:
Phase II
Latest Information Update: 16 Jun 2016
Price :
$35
*
At a glance
- Drugs Capecitabine (Primary) ; Oxaliplatin (Primary)
- Indications Rectal cancer
- Focus Therapeutic Use
- Acronyms OxaliCap-RT
- 31 Jul 2009 Status changed from active, no longer recruiting to completed as reported by United Kingdom Clinical Research Network.
- 29 Apr 2009 New trial record